HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John T Hunt Selected Research

5- isopropyl- 6- (5- methyl- 1,3,4- oxadiazol- 2- yl)- N- (2- methyl- 1H- pyrrolo(2,3- b)pyridin- 5- yl)pyrrolo(2,1- f)(1,2,4)triazin- 4- amine

5/2008Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John T Hunt Research Topics

Disease

20Neoplasms (Cancer)
07/2021 - 08/2002
4Melanoma (Melanoma, Malignant)
07/2021 - 09/2013
4Carcinoma (Carcinomatosis)
09/2013 - 06/2006
2Renal Cell Carcinoma (Grawitz Tumor)
07/2021 - 03/2021
1Leukemia
05/2015
1Fibrosarcoma
09/2013
1Breast Neoplasms (Breast Cancer)
02/2009
1Lung Neoplasms (Lung Cancer)
02/2009

Drug/Important Bio-Agent (IBA)

6Phosphotransferases (Kinase)IBA
01/2019 - 04/2006
3Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
03/2021 - 01/2021
3Heme (Haem)IBA
02/2021 - 01/2018
2linrodostatIBA
02/2021 - 01/2021
2EnzymesIBA
02/2021 - 01/2018
2brivanibIBA
02/2010 - 04/2006
2Antineoplastic Agents (Antineoplastics)IBA
02/2009 - 03/2004
1DioxygenasesIBA
02/2021
1KynurenineIBA
01/2021
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
01/2021
1Mesylates (Mesylate)IBA
01/2021
1AntigensIBA
01/2021
1hematopoietic progenitor kinase 1IBA
01/2019
1Caspase 3 (Caspase-3)IBA
11/2015
1Proteins (Proteins, Gene)FDA Link
11/2015
1BMS-871IBA
05/2015
1compound 30IBA
05/2015
1IpilimumabIBA
09/2013
1matrigelIBA
06/2011
1BMS-690514IBA
06/2011
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2010
1Contrast MediaIBA
02/2010
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
02/2010
1Gadolinium DTPA (Magnevist)FDA Link
02/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2010
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2010
1Paclitaxel (Taxol)FDA LinkGeneric
02/2009
1taxaneIBA
02/2009
1ixabepilone (BMS 247550)FDA Link
02/2009
1Pharmaceutical PreparationsIBA
02/2009
1Excipients (Suspending Agents)IBA
02/2009
1Taxoids (Taxanes)IBA
02/2009
15- isopropyl- 6- (5- methyl- 1,3,4- oxadiazol- 2- yl)- N- (2- methyl- 1H- pyrrolo(2,3- b)pyridin- 5- yl)pyrrolo(2,1- f)(1,2,4)triazin- 4- amineIBA
05/2008
1malonamideIBA
03/2008
1AmidesIBA
03/2008
1ErbB Receptors (EGF Receptor)IBA
10/2006
1(4- ((1- (3- fluorophenyl)methyl)- 1H- indazol- 5- ylamino)- 5- methylpyrrolo(2,1- f)(1,2,4)triazin- 6- yl)carbamic acid 3-morpholinylmethyl esterIBA
10/2006
1Alanine (L-Alanine)FDA Link
04/2006
1ProdrugsIBA
04/2006
1BMS225975IBA
06/2004
1Farnesyltranstransferase (Farnesyltransferase)IBA
06/2004
17- cyano- 2,3,4,5- tetrahydro- 1- (1H- imidazol- 4- ylmethyl)- 3- (phenylmethyl)- 4- (2- thienylsulfonyl)- 1H- 1,4- benzodiazepine (BMS 214662)IBA
06/2004
1Cytostatic AgentsIBA
06/2004
1alvocidib (flavopiridol)IBA
03/2004
1Cyclin EIBA
08/2002

Therapy/Procedure

6Immunotherapy
07/2021 - 01/2019
1Oral Administration
03/2009